PT - JOURNAL ARTICLE AU - Loewenstein, Daniel E. AU - Wieslander, Björn AU - Heiberg, Einar AU - Axelsson, Jimmy AU - Klem, Igor AU - Nijveldt, Robin AU - Schelbert, Erik B. AU - Sörensson, Peder AU - Sigfridsson, Andreas AU - Strauss, David G. AU - Kim, Raymond J. AU - Atwater, Brett D. AU - Ugander, Martin TI - Diagnostic performance of left ventricular mechanical dyssynchrony indices using cardiovascular magnetic resonance feature tracking AID - 10.1101/2022.11.11.22282225 DP - 2022 Jan 01 TA - medRxiv PG - 2022.11.11.22282225 4099 - http://medrxiv.org/content/early/2022/11/11/2022.11.11.22282225.short 4100 - http://medrxiv.org/content/early/2022/11/11/2022.11.11.22282225.full AB - Background Cardiac imaging-based indices of left ventricular (LV) mechanical dyssynchrony have limited accuracy for predicting the response to cardiac resynchronization therapy (CRT). The aim of the study was to evaluate the diagnostic performance of mechanical dyssynchrony indices in a study population of patients with severely reduced ejection fraction and no LV myocardial scar assessed by cardiovascular magnetic resonance (CMR), and either left bundle branch block (LBBB) or normal QRS duration.Methods We retrospectively identified 80 patients from three centers, with LV ejection fraction ≤35%, no scar by CMR late gadolinium enhancement, and either normal electrocardiographic QRS duration (<120ms) and normal frontal plane electrical axis (-30 to +90 degrees) (control, n=36), or LBBB by Strauss’ criteria (LBBB, n=44). The CMR image data from these subjects is made publicly available as part of this publication. CMR feature tracking was used to derive circumferential strain in a midventricular short-axis cine image. Using circumferential strain, mechanical dyssynchrony was quantified as the circumferential uniformity ratio estimate (CURE) and the systolic stretch index (SSI), respectively.Results Both CURE and SSI resulted in measures of mechanical dyssynchrony that were more severe (lower CURE, higher SSI) in LBBB compared to controls (CURE, median [interquartile range], 0.63 [0.54-0.75] vs 0.79 [0.69-0.86], p<0.001; SSI 9.4 [7.4-12.7] vs 2.2 [1.2-3.6], p<0.001). SSI outperformed CURE in the ability to discriminate between LBBB and controls (area under the receiver operating characteristics curve [95% confidence interval] 0.98 [0.95-1.00] vs 0.77 [0.66-0.86], p<0.001; sensitivity 93 [84-100] vs 75 [61-86] %, p=0.02; specificity 97 [92-100] vs 67 [50-81] %, p=0.003).Conclusions The ability to discriminate between LBBB and normal QRS duration among patients with severely reduced ejection fraction and no scar was fair for CURE and excellent for SSI.Competing Interest StatementEH is the founder of the company Medviso AB which develops medical image analysis software. RN has received research grants from Philips Volcano and Biotronik. RJK is a consultant for Abiomed. BDA has received research grants from Boston Scientific and Abbott, and consultation fees from Abbott, Medtronic, Biotronik, and Biosense Webster. MU is principal investigator on a research and development agreement regarding cardiovascular magnetic resonance between Siemens and Karolinska University Hospital. The remaining authors have nothing to disclose that is relevant to the contents of this paper.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Duke University Medical Center gave ethical approval for this work. IRB of University of Pittsburgh Medical Center gave ethical approval for this work Swedish Ethical Review Authority gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed during the current study, as well as code needed to reproduce all aspects of the current study, are available in the Figshare repository, https://doi.org/10.6084/m9.figshare.15155596. The most recent version of the analysis code is available in the Github repository, https://github.com/dloewenstein/dillacs-study. https://doi.org/10.6084/m9.figshare.15155596 https://github.com/dloewenstein/dillacs-study AUCArea under the curveBMIBody Mass IndexBSABody Surface AreaCIConfidence IntervalCMRCardiovascular Magnetic ResonanceCRTCardiac Resynchronization TherapyCURECircumferential Uniformity Ratio EstimateECGElectrocardiographyHFHeart FailureLBBBLeft Bundle Branch BlockLGELate Gadolinium EnhancementLVLeft ventricularLVEDVLeft Ventricular End-Diastolic VolumeLVEDVILeft Ventricular End-Diastolic Volume IndexLVEFLeft Ventricular Ejection FractionLVMLeft Ventricular MassLVMILeft Ventricular Mass IndexOROdds RatioROCReceiver Operating CharacteristicsSPSSystolic Pre-StretchSRSSeptal Rebound StretchSSISystolic Stretch Index